依替巴肽联合瑞舒伐他汀治疗急性心肌梗死临床研究

目的 探讨依替巴肽联合瑞舒伐他汀治疗急性心肌梗死的临床疗效,以及对血清心肌肌钙蛋白T(cTnT)、肌酸激酶同工酶(CK-MB)、心肌营养素1(CT-1)水平的影响.方法 选取河北省任丘市人民医院2018年3月至2020年3月收治的急性心肌梗死患者93例,随机分为研究组(48例)和对照组(45例).两组均给予瑞舒伐他汀治...

Clinical Study of Etibatide Combined with Rosuvastatin in the Treatment of Patients with Acute Myocardial Infarction

Objective To investigate the clinical efficacy of etibatide combined with rosuvastatin in the treatment of patients with acute myocardial infarction(AMI)and the effect on serum cardiac troponin T(cTnT),creatine kinase isoenzyme(CK-MB)and cardiac nutrient-1(CT-1).Methods A total of 93 patients with AMI admitted to the Renqiu People’s Hospital from March 2018 to March 2020 were selected and randomly divided into the study group(48 cases)and the control group(45 cases).The patients in the two groups were treated with rosuvastatin,on this basis,the patients in the study group were treated with etibatide.Both groups were continuously treated for four weeks.Results The total effective rate of the study group was 87.50%,which was higher than 68.89%of the control group(P<0.05).After treatment,the left ventricular ejection fraction(LVEF)and stroke volume(SV)in the study group were significantly higher than those in the control group,while the left ventricular end-diastolic diameter(LVEDd)in the study group was significantly shorter than that in the control group(P<0.05).After treatment,the levels of cTnT and CK-MB in the study group were significantly shorter than those in the control group,while the level of CT-1 in the study group was significantly higher than that in the control group(P<0.05).After treatment,the levels of endothelin-1(ET-1)and von-Willebrand factor(vWF)in the study group were significantly lower than those in the control group,while the level of vascular endothelial growth factor(VEGF)in the study group was significantly higher than that in the control group(P<0.05).The incidence of adverse reactions in the study group was similar to that in the control group(16.67%vs.8.89%,P>0.05).Conclusion Etibatide combined with rosuvastatin is effective and safe in the treatment of patients with AMI,which can improve the cardiac function and the levels of cTnT,CK-MB and CT-1,regulate the endothelial function and promote angiogenesis.